Diagnosis and prognosis of inflammatory bowel diseases: modern view

Abstract

About 5% of the population suffer from chronic diarrhea. Intestinal infections are the most common cause of diarrheal syndrome. However, if they are excluded, it is necessary to check for other possible reasons: vascular, oncological, rheumatic, drug-induced, radiation diseases and other gastroenterological pathology except from inflammatory bowel diseases.

When predicting and detrcting new predictors of unfavorable outcomes and progression of inflammatory bowel diseases, special attention has been recently paid to serological markers and genetic research, which have not yet entered clinical practice due to their high cost.

Inflammatory bowel diseases is a diagnosis of exclusion, which is made after a comprehensive assessment of clinical, laboratory, endoscopic, and morphological data. In case of the development of complications, it needs to investigate new available prognostic markers of inflammatory bowel diseases course.

Keywords

inflammatory bowel disease / ulcerative colitis / Crohn’s disease / prognosis / differential diagnosis

References

[1] Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4):322–337. DOI: 10.1016/j.crohns.2013.01.010

[2] Burisch J., Jess T., Martinato M. et al. The burden of inflammatory bowel disease in Europe // J. Crohns. Colitis. 2013. Vol. 7, No. 4. P. 322–337. DOI: 10.1016/j.crohns.2013.01.010

[3] Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. DOI: 10.1016/S0140-6736(17)32448-0

[4] Ng S.C., Shi H.Y., Hamidi N. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies // Lancet. 2017. Vol. 390, No. 10114. P. 2769–2778. DOI: 10.1016/S0140-6736(17)32448-0

[5] Knyazev OV, Shkurko TV, Fadeyeva NA, et al. Epidemiology of chronic inflammatory bowel disease. Yesterday, today, tomorrow. Experimental and Clinical Gastroenterology. 2017;139(3):4–12. (In Russ.)

[6] Князев О.В., Шкурко Т.В., Фадеева Н.А. и др. Эпидемиология хронических воспалительных заболеваний кишечника. Вчера, сегодня, завтра // Экспериментальная и клиническая гастроэнтерология. 2017. № 3(139). С. 4–12.

[7] Bakulin IG, Zhigalova TN, Latariya EhL, et al. Experience of introduction of the Federal Registry of patients with inflammatory bowel diseases in Saint-Petersburg. Farmateka. 2017;(S5):56–59. (In Russ.)

[8] Бакулин И.Г., Жигалова Т.Н., Латария Э.Л. и др. Опыт внедрения Федерального регистра пациентов с воспалительными заболеваниями кишечника в Санкт-Петербурге // Фарматека. 2017. № S5. С. 56–59.

[9] Maev IV, Shelygin YuA, Skalinskaya MI, et al. The pathomorphosis of inflammatory bowel diseases. Annals of the Russian Academy of Medical Sciences. 2020;75(1):27–35. (In Russ.). DOI: 10.15690/vramn1219

[10] Маев И.В., Шелыгин Ю.А., Скалинская М.И. и др. Патоморфоз воспалительных заболеваний кишечника // Вестник Российской академии медицинских наук. 2020. Т. 75, № 1. C. 27–35. DOI: 10.15690/vramn1219

[11] Klinicheskie rekomendatsii «Yazvennyy kolit» [Internet]. Available from: https://legalacts.ru/doc/klinicheskie-rekomendatsii-iazvennyi-kolit-utv-minzdravom-rossii. Accessed: 18.09.2021. (In Russ.)

[12] Клинические рекомендации «Язвенный колит» [Электронный ресурс] // Официальный интернет-портал правовой информации. Режим доступа: https://legalacts.ru/doc/klinicheskie-rekomendatsii-iazvennyi-kolit-utv-minzdravom-rossii/. Дата обращения: 18.09.2021.

[13] Park SH, Yang SK, Park SK, et al. Atypical distribution of inflammation in newly diagnosed ulcerative colitis is not rare. Can J Gastroenterol Hepatol. 2014;28(3):125–130. DOI: 10.1155/2014/834512

[14] Park S.H., Yang S.K., Park S.K. et al. Atypical distribution of inflammation in newly diagnosed ulcerative colitis is not rare // Can. J. Gastroenterol. Hepatol. 2014. Vol. 28, No. 3. P. 125–130. DOI: 10.1155/2014/834512

[15] Kim B, Barnett JL, Kleer CG, Appelman HD. Endoscopic and histological patchiness in treated ulcerative colitis. Am J Gastroenterol. 1999;94(11):3258–3262. DOI: 10.1111/j.1572-0241.1999.01533.x

[16] Kim B., Barnett J.L., Kleer C.G., Appelman H.D. Endoscopic and histological patchiness in treated ulcerative colitis // Am. J. Gastroenterol. 1999. Vol. 94, No. 11. P. 3258–3262. DOI: 10.1111/j.1572-0241.1999.01533.x

[17] Abdelrazeq AS, Wilson TR, Leitch DL, et al. Ileitis in ulcerative colitis: is it a backwash? Dis Colon Rectum. 2005;48(11):2038–2046. DOI: 10.1007/s10350-005-0160-3

[18] Abdelrazeq A.S., Wilson T.R., Leitch D.L. et al. Ileitis in ulcerative colitis: is it a backwash? // Dis. Colon. Rectum. 2005. Vol. 48, No. 11. P. 2038–2046. DOI: 10.1007/s10350-005-0160-3

[19] Ivashkin VT, Shelygin YuA, Abdulganieva DI, et al. Crohn’s disease. Clinical recommendations (preliminary version). Koloproktologia. 2020;19(2(72)):8–38. (In Russ.). DOI: 10.33878/2073-7556-2020-19-2-8-38

[20] Ивашкин В.Т., Шелыгин Ю.А., Абдулганиева Д.И. и др. Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект) // Колопроктология. 2020. Т. 19, № 2(72). С. 8–38. DOI: 10.33878/2073-7556-2020-19-2-8-38

[21] Lapin SV, Totolyan AA. Immunologicheskaya laboratornaya diagnostika autoimmunnykh zabolevanii. Saint Petersburg; 2010. (In Russ.)

[22] Лапин С.В., Тотолян А.А. Иммунологическая лабораторная диагностика аутоиммунных заболеваний. СПб., 2010.

[23] Fairclough E, Cairns E, Hamilton J, Kelly C. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med (Lond). 2009;9(1):30–33. DOI: 10.7861/clinmedicine.9-1-30

[24] Fairclough E., Cairns E., Hamilton J., Kelly C. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome // Clin. Med. (Lond). 2009. Vol. 9, No. 1. P. 30–33. DOI: 10.7861/clinmedicine.9-1-30

[25] Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig Dis. 2010;28(3):418–423. DOI: 10.1159/000320396

[26] Dotan I. New serologic markers for inflammatory bowel disease diagnosis // Dig. Dis. 2010. Vol. 28, No. 3. P. 418–423. DOI: 10.1159/000320396

[27] Lozoya Angulo ME, de Las Heras Gómez I, Martinez Villanueva M, et al. Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders. Gastroenterol Hepatol. 2017;40(3):125–131. DOI:10.1016/j.gastrohep.2016.04.009

[28] Lozoya Angulo M.E., de Las Heras Gómez I., Martinez Villanueva M. et al. Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders // Gastroenterol. Hepatol. 2017. Vol. 40, No. 3. P. 125–131. DOI: 10.1016/j.gastrohep.2016.04.009

[29] Dai C, Jiang M, Sun MJ, Cao Q. Fecal lactoferrin for assessment of inflammatory bowel disease activity: a systematic review and meta-analysis. J Clin Gastroenterol. 2020;54(6):545–553. DOI: 10.1097/MCG.0000000000001212

[30] Dai C., Jiang M., Sun M.J., Cao Q. Fecal lactoferrin for assessment of inflammatory bowel disease activity: a systematic review and meta-analysis // J. Clin. Gastroenterol. 2020. Vol. 54, No. 6. P. 545–553. DOI: 10.1097/MCG.0000000000001212

[31] Rubio MG, Amo-Mensah K, Gray JM, et al. Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2019;10(5):54–63. DOI: 10.4291/wjgp.v10.i554

[32] Rubio M.G., Amo-Mensah K., Gray J.M. et al. Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease // World J. Gastrointest. Pathophysiol. 2019. Vol. 10, No. 5. P. 54–63. DOI: 10.4291/wjgp.v10.i554

[33] Skalinskaya MI, Skazyvaeva EV, Bakulin IG, et al. The problem of undifferentiated inflammatory bowel disease: from world views to own experience of artificial neural networks application. Preventive and clinical medicine. 2019;2(71):74–81 (In Russ.)

[34] Скалинская М.И., Сказываева Е.В., Бакулин И.Г. и др. Проблема недифференцированных воспалительных заболеваний кишечника: от мировых воззрений до собственного опыта применения искусственных нейронных сетей // Профилактическая и клиническая медицина. 2019. № 2(71). С. 74–81.

[35] Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A–36A. DOI: 10.1155/2005/269076

[36] Silverberg M.S., Satsangi J., Ahmad T. et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology // Can. J. Gastroenterol. 2005. Vol. 19 Suppl A. P. 5A–36A. DOI: 10.1155/2005/269076

[37] Burisch J, Pedersen N, Čuković-Čavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2014;63(4):588–597. DOI: 10.1136/gutjnl-2013-304636

[38] Burisch J., Pedersen N., Čuković-Čavka S. et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort // Gut. 2014. Vol. 63, No. 4. P. 588–597. DOI: 10.1136/gutjnl-2013-304636

[39] Burisch J, Zammit SC, Ellul P, et al. Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study. J Gastroenterol Hepatol. 2019;34(6):996–1003. DOI: 10.1111/jgh.14563

[40] Burisch J., Zammit S.C., Ellul P. et al. Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study // J. Gastroenterol. Hepatol. 2019. Vol. 34, No. 6. P. 996–1003. DOI: 10.1111/jgh.14563

[41] Melmed GY, Elashoff R, Chen GC, et al. Predicting a change in diagnosis from ulcerative colitis to Crohn’s disease: a nested, case-control study. Clin Gastroenterol Hepatol. 2007;5(5):602–608;quiz 525. DOI: 10.1016/j.cgh.2007.02.015

[42] Melmed G.Y., Elashoff R., Chen G.C. et al. Predicting a change in diagnosis from ulcerative colitis to Crohn’s disease: a nested, case-control study // Clin. Gastroenterol. Hepatol. 2007. Vol. 5, No. 5. P. 602–608; quiz 525. DOI: 10.1016/j.cgh.2007.02.015

[43] Miehlke S, Verhaegh B, Tontini GE,et al. Microscopic colitis: pathophysiology and clinical management. Lancet Gastroenterol Hepatol. 2019;4(4):305–314. DOI: 10.1016/S2468-1253(19)30048-2

[44] Miehlke S., Verhaegh B., Tontini G.E. et al. Microscopic colitis: pathophysiology and clinical management // Lancet Gastroenterol. Hepatol. 2019. Vol. 4, No. 4. P. 305–314. DOI: 10.1016/S2468-1253(19)30048-2

[45] Korochanskaya NV, Durleshter VM. Ishemicheskiy kolit: sovremennye podkhody k diagnostike i lecheniyu: uchebno-metodicheskoe posobie dlya vrachey. Moscow: Prima Print; 2016. (In Russ.)

[46] Корочанская Н.В., Дурлештер В.М. Ишемический колит: современные подходы к диагностике и лечению: учебно-методическое пособие для врачей. М.: Прима Принт, 2016.

[47] Hansen KJ, Wilson DB, Craven TE, et al. Mesenteric artery disease in the elderly. J Vasc Surg. 2004;40(1):45–52. DOI: 10.1016/j.jvs.2004.03.022

[48] Hansen K.J., Wilson D.B., Craven T.E. et al. Mesenteric artery disease in the elderly // J. Vasc. Surg. 2004. Vol. 40, No. 1. P. 45–52. DOI: 10.1016/j.jvs.2004.03.022

[49] Munipalle PC, Garud T, Light D. Diaphragmatic disease of the colon: systematic review. Colorectal Dis. 2013;15(9):1063–1069. DOI: 10.1111/codi.12218

[50] Munipalle P.C., Garud T., Light D. Diaphragmatic disease of the colon: systematic review // Colorectal. Dis. 2013. Vol. 15, No. 9. P. 1063–1069. DOI: 10.1111/codi.12218

[51] Tandon P, Bourassa-Blanchette S, Bishay K, et al. The Risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. J Immunother. 2018;41(3):101–108. DOI: 10.1097/CJI.0000000000000213

[52] Tandon P., Bourassa-Blanchette S., Bishay K. et al. The Risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis // J. Immunother. 2018. Vol. 41, No. 3. P. 101–108. DOI: 10.1097/CJI.0000000000000213

[53] Wright AP, Piper MS, Bishu S, Stidham RW. Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2019;49(12):1474–1483. DOI: 10.1111/apt.15263

[54] Wright A.P., Piper M.S., Bishu S., Stidham R.W. Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis // Aliment. Pharmacol. Ther. 2019. Vol. 49, No. 12. P. 1474–1483. DOI: 10.1111/apt.15263

[55] Bavi P, Butler M, Serra S, Chetty R. Immune modulator-induced changes in the gastrointestinal tract. Histopathology. 2017;71(3):494–496. DOI: 10.1111/his.13224

[56] Bavi P., Butler M., Serra S., Chetty R. Immune modulator-induced changes in the gastrointestinal tract // Histopathology. 2017. Vol. 71, No. 3. P. 494–496. DOI: 10.1111/his.13224

[57] Gecse KB, Vermeire S. Differential diagnosis of inflammatory bowel disease: imitations and complications. Lancet Gastroenterol Hepatol. 2018;3(9):644–653. DOI: 10.1016/S2468-1253(18)30159-6

[58] Gecse K.B., Vermeire S. Differential diagnosis of inflammatory bowel disease: imitations and complications // Lancet Gastroenterol. Hepatol. 2018. Vol. 3, No. 9. P. 644–653. DOI: 10.1016/S2468-1253(18)30159-6

[59] Calmet FH, Yarur AJ, Pukazhendhi G, et al. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation. Ann Gastroenterol. 2015;28(3):366–373.

[60] Calmet F.H., Yarur A.J., Pukazhendhi G. et al. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation // Ann. Gastroenterol. 2015. Vol. 28, No. 3. P. 366–373.

[61] Topchij TB, Sycheva IV, Ruhadze GO, et al. Luchevye proktity: posobie dlja vrachej. Moscow: Prima Print; 2019. (In Russ.)

[62] Топчий Т.Б., Сычева И.В., Рухадзе Г.О. и др. Лучевые проктиты: пособие для врачей. М.: Прима Принт, 2019.

[63] Nelamangala Ramakrishnaiah VP, Krishnamachari S. Chronic haemorrhagic radiation proctitis: A review. World J Gastrointest Surg. 2016;8(7):483–491. DOI: 10.4240/wjgs.v8.i7.483

[64] Nelamangala Ramakrishnaiah V.P., Krishnamachari S. Chronic haemorrhagic radiation proctitis: A review // World J. Gastrointest. Surg. 2016. Vol. 8, No. 7. P. 483–491. DOI: 10.4240/wjgs.v8.i7.483

[65] Zabolevaemost’ naselenija otdel’nymi infekcionnymi zabolevanijami v 2016 godu [Internet]. Federal’naja sluzhba gosudarstvennoj statistiki. Available from: http://www.gks.ru/bgd/regl/b17_01/IssWWW.exe/Stg/d01/3-3.doc. Accessed: 18.09.2021. (In Russ.)

[66] Заболеваемость населения отдельными инфекционными заболеваниями в 2016 году [Электронный ресурс] // Федеральная служба государственной статистики. Режим доступа: http://www.gks.ru/bgd/regl/b17_01/IssWWW.exe/Stg/d01/3-3.doc. Дата обращения 18.09.2021.

[67] Klinicheskij protokol diagnostiki i lechenija. Diareja i gastrojenterit predpolozhitel’no infekcionnogo proishozhdenija [Internet]. Available from: http://www.rcrz.kz/docs/clinic_protocol/2015/285.pdf. Accessed: 18.10.2021. (In Russ.)

[68] Клинический протокол диагностики и лечения. Диарея и гастроэнтерит предположительно инфекционного происхождения. 2015. [Электронный ресурс]. Режим доступа: http://www.rcrz.kz/docs/clinic_protocol/2015/285.pdf.

[69] Hajifathalian K, Mahadev S, Schwartz RE, et al. SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant. World J Gastroenterol. 2020;26(14):1546–1553. DOI: 10.3748/wjg.v26.i14.1546

[70] Hajifathalian K., Mahadev S., Schwartz R.E. et al. SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant // World J. Gastroenterol. 2020. Vol. 26, No. 14. P. 1546–1553. DOI: 10.3748/wjg.v26.i14.1546

[71] Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med. 2006;354(2):119–130. DOI: 10.1056/NEJMoa051331

[72] Freedman D.O., Weld L.H., Kozarsky P.E. et al. Spectrum of disease and relation to place of exposure among ill returned travelers // N. Engl. J. Med. 2006. Vol. 354, No. 2. P. 119–130. DOI: 10.1056/NEJMoa051331

[73] Stermer E, Lubezky A, Potasman I, et al. Is traveler’s diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis. 2006;43(7):898–901. DOI: 10.1086/507540

[74] Stermer E., Lubezky A., Potasman I. et al. Is traveler’s diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study // Clin. Infect. Dis. 2006. Vol. 43, No. 7. P. 898–901. DOI: 10.1086/507540

[75] Oh SJ, Lee CK, Kim YW, et al. True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares: the 10-year experience of an academic referral inflammatory bowel disease center. Scand J Gastroenterol. 2019;54(8):976–983. DOI: 10.1080/00365521.2019.1646798

[76] Oh S.J., Lee C.K., Kim Y.W. et al. True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares: the 10-year experience of an academic referral inflammatory bowel disease center // Scand. J. Gastroenterol. 2019. Vol. 54, No. 8. P. 976–983. DOI: 10.1080/00365521.2019.1646798

[77] Beswick L, Ye B, van Langenberg DR. Toward an algorithm for the diagnosis and management of CMV in patients with colitis. Inflamm Bowel Dis. 2016;22(12):2966–2976. DOI: 10.1097/MIB.0000000000000958

[78] Beswick L., Ye B., van Langenberg D.R. Toward an algorithm for the diagnosis and management of CMV in patients with colitis // Inflamm. Bowel Dis. 2016. Vol. 22, No. 12. P. 2966–2976. DOI: 10.1097/MIB.0000000000000958

[79] Zagórowicz E, Bugajski M, Wieszczy P, et al. Cytomegalovirus infection in ulcerative colitis is related to severe inflammation and a high count of cytomegalovirus-positive cells in biopsy is a risk factor for colectomy. J Crohns Colitis. 2016;10(10):1205–1211. DOI: 10.1093/ecco-jcc/jjw071

[80] Zagórowicz E., Bugajski M., Wieszczy P. et al. Cytomegalovirus infection in ulcerative colitis is related to severe inflammation and a high count of cytomegalovirus-positive cells in biopsy is a risk factor for colectomy // J. Crohns. Colitis. 2016. Vol. 10, No. 10. P. 1205–1211. DOI: 10.1093/ecco-jcc/jjw071

[81] Störkmann H, Rödel J, Stallmach A, Reuken PA. Are CMV-predictive scores in inflammatory bowel disease useful in clinical practice? Z Gastroenterol. 2020;58(9):868–871. DOI: 10.1055/a-1221-5463

[82] Störkmann H., Rödel J., Stallmach A., Reuken P.A. Are CMV-predictive scores in inflammatory bowel disease useful in clinical practice? // Z. Gastroenterol. 2020. Vol. 58, No. 9. P. 868–871. DOI: 10.1055/a-1221-5463

[83] Shivaji UN, Sharratt CL, Thomas T, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(6):664–680. DOI: 10.1111/apt.15097

[84] Shivaji U.N., Sharratt C.L., Thomas T. et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease // Aliment. Pharmacol. Ther. 2019. Vol. 49, No. 6. P. 664–680. DOI: 10.1111/apt.15097

[85] Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver. 2014;8(1):1–6. DOI: 10.5009/gnl.2014.8.1.1

[86] Burke K.E., Lamont J.T. Clostridium difficile infection: a worldwide disease // Gut. Liver. 2014. Vol. 8, No. 1. P. 1–6. DOI: 10.5009/gnl.2014.8.1.1

[87] Furuya-Kanamori L, Stone JC, Clark J, et al. Comorbidities, exposure to medications, and the risk of community-acquired clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36(2):132–141. DOI: 10.1017/ice.2014.39

[88] Furuya-Kanamori L., Stone J.C., Clark J. et al. Comorbidities, exposure to medications, and the risk of community-acquired clostridium difficile infection: a systematic review and meta-analysis // Infect. Control. Hosp. Epidemiol. 2015. Vol. 36, No. 2. P. 132–141. DOI: 10.1017/ice.2014.39

[89] Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742–748. DOI: 10.1093/jac/dkr508

[90] Hensgens M.P., Goorhuis A., Dekkers O.M., Kuijper E.J. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics // J. Antimicrob. Chemother. 2012. Vol. 67, No. 3. P. 742–748. DOI: 10.1093/jac/dkr508

[91] Federal’nye klinicheskie rekomendacii po diagnostike i lecheniju sistemnyh vaskulitov. 2013 [Internet]. Available from: https://www.mrckb.ru/files/vaskulity.doc. Accessed: 18.10.2021. (In Russ.)

[92] Федеральные клинические рекомендации по диагностике и лечению системных васкулитов. 2013. [Электронный ресурс]. Режим доступа: https://www.mrckb.ru/files/vaskulity.doc.

[93] Levine SM, Hellmann DB, Stone JH. Gastrointestinal involvement in polyarteritis nodosa (1986-2000): presentation and outcomes in 24 patients. Am J Med. 2002;112(5):386–391. DOI: 10.1016/s0002-9343(01)01131-7

[94] Levine S.M., Hellmann D.B., Stone J.H. Gastrointestinal involvement in polyarteritis nodosa (1986-2000): presentation and outcomes in 24 patients // Am. J. Med. 2002. Vol. 112, No. 5. P. 386–391. DOI: 10.1016/s0002-9343(01)01131-7

[95] Klinicheskie rekomendatsii “Bolezn’ Bekhcheta”. 2018 [Internet]. Available from: https://legalacts.ru/doc/klinicheskie-rekomendatsii-bolezn-bekhcheta-bb-utv-minzdravom-rossii/. Accessed: 18.09.2021. (In Russ.)

[96] Клинические рекомендации «Болезнь Бехчета». 2018. [Электронный ресурс]. Режим доступа: https://legalacts.ru/doc/klinicheskie-rekomendatsii-bolezn-bekhcheta-bb-utv-minzdravom-rossii/. Дата обращения: 18.09.2021.

[97] Feng R, Chao K, Chen SL, et al. Heat shock protein family A member 6 combined with clinical characteristics for the differential diagnosis of intestinal Behçet’s disease. J Dig Dis. 2018;19(6):350–358. DOI: 10.1111/1751-2980.12613

[98] Feng R., Chao K., Chen S.L. et al. Heat shock protein family A member 6 combined with clinical characteristics for the differential diagnosis of intestinal Behçet’s disease // J. Dig. Dis. 2018. Vol. 19, No. 6. P. 350–358. DOI: 10.1111/1751-2980.12613

[99] Ye JF, Guan JL. Differentiation between intestinal Behçet’s disease and Crohn’sdisease based on endoscopy. Turk J Med Sci. 2019;49(1):42–49. DOI: 10.3906/sag-1807-67

[100] Ye J.F., Guan J.L. Differentiation between intestinal Behçet’s disease and Crohn’sdisease based on endoscopy // Turk. J. Med. Sci. 2019. Vol. 49, No. 1. P. 42–49. DOI: 10.3906/sag-1807-67

[101] Rustom LBO, Sharara AI. The Natural history of colonic diverticulosis: Much ado about nothing? Inflamm Intest Dis. 2018;3(2):69–74. DOI: 10.1159/000490054

[102] Rustom L.B.O., Sharara A.I. The Natural history of colonic diverticulosis: Much ado about nothing? // Inflamm. Intest. Dis. 2018. Vol. 3, No. 2. P. 69–74. DOI: 10.1159/000490054

[103] Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010;375(9719):1030–1047. DOI: 10.1016/S0140-6736(10)60353-4

[104] Cunningham D., Atkin W., Lenz H.J. et al. Colorectal cancer // Lancet. 2010. Vol. 375, No. 9719. P. 1030–1047. DOI: 10.1016/S0140-6736(10)60353-4

[105] Theede K, Holck S, Ibsen P, et al. Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2016;22(5):1042–1048. DOI: 10.1097/MIB.0000000000000736

[106] Theede K., Holck S., Ibsen P. et al. Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis // Inflamm. Bowel Dis. 2016. Vol. 22, No. 5. P. 1042–1048. DOI: 10.1097/MIB.0000000000000736

[107] Mak WY, Buisson A, Andersen MJ Jr, et al. Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis. Dig Dis Sci. 2018;63(5):1294–1301. DOI: 10.1007/s10620-018-4980-0

[108] Mak W.Y., Buisson A., Andersen M.J. Jr. et al. Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis // Dig. Dis. Sci. 2018. Vol. 63, No. 5. P. 1294–1301. DOI: 10.1007/s10620-018-4980-0

[109] Ye YL, Yin J, Hu T, et al. Increased circulating circular RNA_103516 is a novel biomarker for inflammatory bowel disease in adult patients. World J Gastroenterol. 2019;25(41):6273–6288. DOI: 10.3748/wjg.v25.i41.6273

[110] Ye Y.L., Yin J., Hu T. et al. Increased circulating circular RNA_103516 is a novel biomarker for inflammatory bowel disease in adult patients // World J. Gastroenterol. 2019. Vol. 25, No. 41. P. 6273–6288. DOI: 10.3748/wjg.v25.i41.6273

[111] Xu Y, Xu X, Ocansey DKW, et al. CircRNAs as promising biomarkers of inflammatory bowel disease and its associated-colorectal cancer. Am J Transl Res. 2021;13(3):1580–1593.

[112] Xu Y., Xu X., Ocansey D.K.W. et al. CircRNAs as promising biomarkers of inflammatory bowel disease and its associated-colorectal cancer // Am. J. Transl. Res. 2021. Vol. 13, No. 3. P. 1580–1593.

[113] Edwards SJ, Barton S, Bacelar M, et al. Prognostic tools for identification of high risk in people with Crohn’s disease: systematic review and cost-effectiveness study. Health Technol Assess. 2021;25(23):1–138. DOI: 10.3310/hta25230

[114] Edwards S.J., Barton S., Bacelar M. et al. Prognostic tools for identification of high risk in people with Crohn’s disease: systematic review and cost-effectiveness study // Health Technol. Assess. 2021. Vol. 25, No. 23. P. 1–138. DOI: 10.3310/hta25230

[115] Verbeeten DS. Genetic and serological markers associated with pouchitis and a Crohn’s disease-like phenotype after pelvic pouch surgery for ulcerative colitis. [dissertation] Toronto: University of Tornonto; 2009.

[116] Verbeeten D.S. Genetic and serological markers associated with pouchitis and a Crohn’s disease-like phenotype after pelvic pouch surgery for ulcerative colitis. [dissertation] Toronto: University of Tornonto, 2009.

[117] Morilla I, Uzzan M, Laharie D, et al. Colonic MicroRNA profiles, identified by a deep learning algorithm, that predict responses to therapy of patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17(5):905–913. DOI: 10.1016/j.cgh.2018.08.068

[118] Morilla I., Uzzan M., Laharie D. et al. Colonic MicroRNA profiles, identified by a deep learning algorithm, that predict responses to therapy of patients with acute severe ulcerative colitis // Clin. Gastroenterol. Hepatol. 2019. Vol. 17, No. 5. P. 905–913. DOI: 10.1016/j.cgh.2018.08.068

RIGHTS & PERMISSIONS

Bakulin I.G., Rasmagina I.A., Skalinskaya M.I.